Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + albumin-bound paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cadonilimab + albumin-bound paclitaxel + carboplatin is a combination regimen used in oncology clinical trials, primarily for the treatment of advanced or metastatic cancers such as cervical cancer and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Cadonilimab is a first-in-class bispecific monoclonal antibody that targets both PD-1 and CTLA-4 immune checkpoints, enhancing antitumor immunity by blocking inhibitory signals on T cells. Albumin-bound paclitaxel (nab-paclitaxel) is a microtubule inhibitor that disrupts cell division, while carboplatin is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in rapidly dividing cells. This combination leverages immunotherapy with cytotoxic chemotherapy to improve response rates in patients with difficult-to-treat malignancies[2][4]. Cadonilimab was developed by Akeso and has been approved for certain indications in China; its use with chemotherapy regimens like albumin-bound paclitaxel plus carboplatin remains under investigation in multiple phase II/III trials[1][2][4].
- Brand names
- Kaitanni + Abraxane + Carboplatin
- Other names
- cadonilimab + nab-paclitaxel + carboplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cadonilimab + albumin-bound paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + albumin-bound paclitaxel + carboplatin.